News & Updates

Adding lutetium-177 (¹⁷⁷Lu)–Dotatate radioligand therapy (RLT) to long-acting octreotide as first-line therapy significantly improves progression-free survival (PFS) in patients with newly diagnosed somatostatin receptor-positive (SSTR+), grade 2 and 3 (G2 and G3), well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs) compared with high-dose long-acting octreotide alone, according to the NETTER-2 trial presented at ASCO GI 2024.

Patients with cirrhosis who are exposed to high-dose proton pump inhibitors (PPIs) are at increased risk of death and cirrhotic complications, as suggested in a retrospective study.

Readmissions within 30 days are common among patients with cirrhosis, but most of these are not preventable, reveals a study.

Taking proton pump inhibitors for a long period of time appears to increase the risk of nonalcoholic fatty liver disease (NAFLD), particularly severe hepatic steatosis, reveals a US study.

First-line pembrolizumab (pembro) plus chemotherapy (chemo) in patients with untreated advanced esophageal cancer demonstrates robust efficacy after 5 years, with no new safety concerns, when compared with placebo plus chemo, according to a study presented at ASCO GI 2024.